The partners will create a secure, Rush-hosted clinical analytics platform to enable Rush researchers to analyze deidentified, longitudinal, and multimodal clinical data.
The bank gave CareDx a price target of $65 per share and BillionToOne of $120 per share, noting their strong positions in non-oncology markets and recent moves into cancer testing.
The program aims to bolster domestic biomanufacturing and supply chain capabilities and speed point-of-care therapeutics production.
The Dow Jones Industrial Average rose 1 percent month over month, the Nasdaq rose 4 percent, and the Nasdaq Biotech Index rose 10 percent.
A polygenic risk score provided insights into hypertrophic cardiomyopathy risk and adverse cardiovascular outcomes in individuals with or without Mendelian disease contributors.
With ongoing reagent challenges postponing its proteome-scale ambitions indefinitely, the firm has shifted the majority of its R&D resources to developing its targeted technology.
Top Five Articles Last Week: Antibody Image Manipulation, Guardant Health to Pay $245M Damages, More
Last week, GenomeWeb’s readers were most interested in learning about a new report suggesting manipulation of antibody validation images is widespread among providers.
NEW YORK – Heidelberg Epignostix said on Tuesday that it has inked a strategic partnership with the UK National Health Service's Genomic Medicine Service (GMS) to bring the company's epigenetic ...
Qiagen has appointed Jonathan Pratt to serve as CEO, succeeding Thierry Bernard. Pratt previously served as president and CEO at Filtration Group, senior VP of the Waters Division at Waters ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results